瑞丹韦单抗
瑞丹韦单抗（INN：Regdanvimab），以商品名Regkirona出售，是一种用于治疗COVID-19的人单克隆抗体。[4]该抗体针对SARS-CoV-2的刺突蛋白。它是由赛特瑞恩（Celltrion）开发的。[6][7]该药物通过静脉输注（滴注）给药。[4][8]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | SARS-CoV-2的刺突蛋白 |
| 临床资料 | |
| 商品名 | Regkirona |
| 其他名称 | 瑞达韦单抗、瑞丹维单抗、CT-P59 |
| 核准状况 | |
| 怀孕分级 | |
| 给药途径 | 静脉注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 | |
| 识别信息 | |
| CAS号 | 2444308-95-4 |
| DrugBank | |
| UNII | |
| KEGG | |
参考资料
- ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. （原始内容存档于3 April 2022）.
- ^ AusPAR: Regdanvimab. Therapeutic Goods Administration (TGA). 7 December 2021 [4 January 2022]. （原始内容存档于5 January 2022）.
- ^ TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona). Therapeutic Goods Administration (TGA) (新闻稿). 6 December 2021 [4 January 2022]. （原始内容存档于5 January 2022）.
- ^ 4.0 4.1 4.2 4.3 4.4 Regkirona EPAR. European Medicines Agency. 10 November 2021 [12 November 2021]. （原始内容存档于12 November 2021）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 5.0 5.1 Regkirona. Union Register of medicinal products. 12 November 2021 [24 April 2022]. （原始内容存档于24 April 2022）.
- ^ Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform (新闻稿). Celltrion. 11 February 2021 [4 March 2021]. （原始内容存档于19 October 2021） –通过Business Wire.
- ^ Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 (新闻稿). Celltrion. 13 January 2021 [4 March 2021]. （原始内容存档于19 October 2021） –通过Business Wire.
- ^ EMA issues advice on use of regdanvimab for treating COVID-19. European Medicines Agency. 26 March 2021 [15 October 2021]. （原始内容存档于15 November 2021）.
延伸阅读
- Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications //www.ncbi.nlm.nih.gov/pmc/articles/PMC7803729
|PMC=缺少标题 (帮助). January 2021, 12 (1): 288. PMC 7803729
. PMID 33436577. doi:10.1038/s41467-020-20602-5 . - Syed YY. Regdanvimab: First Approval. Drugs //www.ncbi.nlm.nih.gov/pmc/articles/PMC8558754
|PMC=缺少标题 (帮助). December 2021, 81 (18): 2133–7. PMC 8558754 . PMID 34724174. doi:10.1007/s40265-021-01626-7 .
外部链接
- Regdanvimab. Drug Information Portal. U.S. National Library of Medicine. [2023-12-19]. （原始内容存档于2022-11-27）.